Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes - the latter adds a third agreement in the companies' partnership, which will now include the development of drugs for three undisclosed targets to treat neurological or neuromuscular disorders. Biogen will pay Isis $30M upfront, another $200M in milestones for each program, and double-digit royalties on drug sales. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 7:14AM)
at Zacks.com (Mon, 10:40AM)
at Zacks.com (Feb 25, 2015)
at Nasdaq.com (Feb 5, 2015)
at Investor's Business Daily (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs